Insider Selling: Becton, Dickinson and Company (NYSE:BDX) CEO Sells $768,120.00 in Stock

Becton, Dickinson and Company (NYSE:BDX) CEO Thomas Polen, Jr. sold 4,152 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Becton, Dickinson and Company Stock Up 0.7%

Shares of NYSE:BDX traded up $1.20 during trading on Friday, reaching $183.16. The stock had a trading volume of 1,008,994 shares, compared to its average volume of 2,680,036. The firm’s 50-day simple moving average is $157.20 and its 200 day simple moving average is $161.55. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The company has a market capitalization of $50.47 billion, a P/E ratio of 55.17, a PEG ratio of 12.94 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.84%. Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Institutional Trading of Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company in the third quarter valued at about $25,000. SHP Wealth Management purchased a new stake in Becton, Dickinson and Company in the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc acquired a new position in Becton, Dickinson and Company in the 4th quarter worth approximately $29,000. WPG Advisers LLC raised its position in Becton, Dickinson and Company by 64.2% during the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 61 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in Becton, Dickinson and Company during the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BDX. Citigroup reaffirmed a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday. The Goldman Sachs Group lowered their price target on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a report on Wednesday, May 27th. TD Cowen upped their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective for the company. Finally, Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $185.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.